|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 61 | 2020 | Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab | Wiendl, Heinz; Carraro, Matthew; Comi, Giancarlo; Izquierdo, Guillermo; Kim, Ho Jin; Sharrack, Basil; Tornatore, Carlo; Daizadeh, Nadia; Chung, Luke; Jacobs, Alan K.; Hogan, Richard J.; Wychowski, Linda V.; VAN WIJMEERSCH, Bart | Journal Contribution | A1 |
| 62 | 2020 | Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study | Ziemssen, Tjalf; Bass, Ann D.; Berkovich, Regina; Comi, Giancarlo; Eichau, Sara; Hobart, Jeremy; Hunter, Samuel F.; LaGanke, Christopher; Limmroth, Volker; Pelletier, Daniel; Pozzilli, Carlo; Schippling, Sven; Sousa, Livia; Traboulsee, Anthony; Uitdehaag, Bernard M. J.; VAN WIJMEERSCH, Bart; Choudhry, Zia; Daizadeh, Nadia; Singer, Barry A. | Journal Contribution | A1 |
| 63 | 2020 | Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies | VAN WIJMEERSCH, Bart; Singer, Barry A.; Boster, Aaron; Broadley, Simon; Fernandez, Oscar; Freedman, Mark S.; Izquierdo, Guillermo; Lycke, Jan; Pozzilli, Carlo; Sharrack, Basil; Steingo, Brian; Wiendl, Heinz; Wray, Sibyl; Ziemssen, Tjalf; Chung, Luke; Margolin, David H.; Thangavelu, Karthinathan; Vermersch, Patrick | Journal Contribution | A1 |
| 64 | 2020 | Risk of secondary progressive multiple sclerosis: A longitudinal study | Fambiatos, Adam; Jokubaitis, Vilija; Horakova, Dana; Havrdova, Eva Kubala; Trojano, Maria; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Lugaresi, Alessandra; Izquierdo, Guillermo; Grand'Maison, Francois; Grammond, Pierre; Sola, Patrizia; Ferraro, Diana; Alroughani, Raed; Terzi, Murat; Hupperts, Raymond; Boz, Cavit; Lechner-Scott, Jeannette; Pucci, Eugenio; Bergamaschi, Roberto; Van Pesch, Vincent; Ozakbas, Serkan; Granella, Franco; Turkoglu, Recai; Iuliano, Gerardo; Spitaleri, Daniele; McCombe, Pamela; Solaro, Claudio; Slee, Mark; Ampapa, Radek; Soysal, Aysun; Petersen, Thor; Sanchez-Menoyo, Jose Luis; Verheul, Freek; Prevost, Julie; Sidhom, Youssef; VAN WIJMEERSCH, Bart; Vucic, Steve; Cristiano, Edgardo; Saladino, Maria Laura; Deri, Norma; Barnett, Michael; Olascoaga, Javier; Moore, Fraser; Skibina, Olga; Gray, Orla; Fragoso, Yara; Yamout, Bassem; Shaw, Cameron; Singhal, Bhim; Shuey, Neil; Hodgkinson, Suzanne; Altintas, Ayse; Al-Harbi, Talal; Csepany, Tunde; Taylor, Bruce; Hughes, Jordana; Jun, Jae-Kwan; van der Walt, Anneke; Spelman, Tim; Butzkueven, Helmut; Kalincik, Tomas | Journal Contribution | A1 |
| 65 | 2020 | Deciphering the Morphology of Motor Evoked Potentials | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; HELLINGS, Niels; Cambron, M; Dive, D; Laureys, G.; POPESCU, Veronica; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | A1 |
| 66 | 2020 | Comparing 16 Different Dual–Tasking Paradigms in Individuals With Multiple Sclerosis and Healthy Controls: Working Memory Tasks Indicate Cognitive–Motor Interference | LEONE, Carmela; MOUMDJIAN, Lousin; Patti, Francesco; VANZEIR, Ellen; BAERT, Ilse; VELDKAMP, Renee; VAN WIJMEERSCH, Bart; FEYS, Peter | Journal Contribution | A1 |
| 67 | 2020 | Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; POPESCU, Veronica; HELLINGS, Niels; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | A1 |
| 68 | 2019 | Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) | Pelletier, Daniel; Arnold, Douglas L.; Boyko, Alexey N.; Comi, Giancarlo; Hartung, Hans-Peter; Havrdova, Eva Kubala; Inshasi, Jihad Said; McCombe, Pamela; Nakamura, Kunio; Oreja-Guevara, Celia; Pozzilli, Carlo; Selmaj, Krzysztof W.; Scott, Thomas F.; Chung, Luke; Daizadeh, Nadia; Afsar, Salman; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 69 | 2019 | No Association Between Lymphocyte Pharmacodynamics and Disability Following Alemtuzumab Treatment in patients With Relapsing-Remitting Multiple Sclerosis | Meuth, Sven G.; Brandes, David; Carraro, Matthew; Comi, Giancarlo; Mao-Draayer, Yang; Izquierdo, Guillermo; Kim, Ho Jin; Pardo, Gabriel; Sharrack, Basil; Tornatore, Carlo; VAN WIJMEERSCH, Bart; Ziemssen, Tjalf; Jacobs, Alan; Chung, Luke; Daizadeh, Nadia; Wiendl, Heinz | Journal Contribution | M |
| 70 | 2019 | Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting | VAN WIJMEERSCH, Bart; Patti, F.; Hobart, J.; Kizlaitiene, R.; Vanderdonckt, P.; Shor, S.; Andreasen, A. K.; Uitdehaag, B. M. | Journal Contribution | M |
| 71 | 2019 | Neuromyelitis Optica in Flanders: an epidemiological study | Blomme, L.; MOONS, Lynn; Noels, S.; Laureys, G.; VAN WIJMEERSCH, Bart; Crols, R.; DE KLIPPEL, Nina; Van de Velde, K.; Willekens, B. | Journal Contribution | M |
| 72 | 2019 | Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study) | Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H. -P.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 73 | 2019 | Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years | Vermersch, P.; Baker, M.; Bass, A. D.; Berkovich, R.; Comi, G.; Eichau, S.; Graves, D.; Hunter, S. F.; Ionete, C.; Limmroth, V.; Meuth, S. G.; Naismith, R. T.; Sharrack, B.; Subei, A.; Daizadeh, N.; Choudhry, Z.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 74 | 2019 | Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study) | Montalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 75 | 2019 | Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) | McCombe, P.; Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H-P; Havrdova, E. K.; Inshasi, J. S.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 76 | 2019 | Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies | VAN WIJMEERSCH, Bart; Buffels, R.; Clinch, S.; Kuhelj, R.; Wei, W.; Vermersch, P. | Journal Contribution | M |
| 77 | 2019 | Therapeutic lag in relapsing multiple sclerosis | ROOSEN, Inge; Frascoli, F.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Eichau, S.; Patti, F.; Onofr, M.; Lugaresi, A.; Prat, A.; Girard, M.; Duquette, P.; Ozakbas, S.; Grammond, P.; Sola, P.; Ferraro, D.; Bergamaschi, R.; Boz, C.; Cartechini, E.; Sa, M. J.; Terzi, M.; Alroughani, R.; Grand'Maison, F.; Granella, F.; Iuliano, G.; Hupperts, R.; Lechner-Scott, J.; Spitaleri, D.; Van Pesch, V.; Soysal, A.; Prevost, J.; Aguera-Morales, E.; Olascoaga, J.; Turkoglu, R.; Sidhom, Y.; Gouider, R.; VAN WIJMEERSCH, Bart; Butzkueven, H.; Malpas, C.; Kalincik, T. | Journal Contribution | M |
| 78 | 2019 | Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial | Cambron, Melissa; Mostert, Jop; D'Hooghe, Marie; Nagels, Guy; Willkens, Barbara; Debruyne, Jan; Algoed, Luc; Verhagen, Winn; Hupperts, Raymond; Heersema, Dorothea; De Keyser, Jacques; De Groot, Liesbeth; Foselle, Erwin; Guillaume, Daniel; Merckx, Henri; Vanopdenbosch, Ludo; Vokaer, Mathieu; DE KLIPPEL, Nina; Nuytten, Dirk; Van Remoortel, Ann; Symons, Anoek; D'haeseleer, Miguel; Bissay, Veronique; Van Merhaegen-Wieleman, Annick; Van Lint, Michel; Michiels, Veronique; Haentjens, Patrick; VAN WIJMEERSCH, Bart; Tillemans, Bart; Van Hecke, Wim; Hengstman, Gerald | Journal Contribution | A1 |
| 79 | 2019 | Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS | Kalincik, T.; Malpas, C. B.; ROOSEN, Inge; Patti, F.; Butzkueven, H.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Onofrj, M.; Lugaresi, A.; Hupperts, R.; Lechner-Scott, J.; Sola, P.; Ferraro, D.; Grammond, P.; Csepany, T.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; VAN WIJMEERSCH, Bart; Granella, F.; Sa, M. J.; Bergamaschi, R.; Slee, M.; Boz, C.; Ozakbas, S.; Terzi, M.; Prevost, J.; Solaro, C.; Macdonell, R.; Cartechini, E.; Coles, A.; Havrdova, E. K.; Horakova, D. | Journal Contribution | M |
| 80 | 2019 | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results) | Vermersch, P.; Eralinna, J. -P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W.; Comi, G. | Journal Contribution | M |
Loading...
5
0
5
0
false